La Jolla Pharmaceutical (LJPC) Gross Profit Margin starting from the second quarter 2022 to second quarter 2021, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
La Jolla Pharmaceutical Company  (NASDAQ: LJPC)


La Jolla Pharmaceutical's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LJPC Gross Profit Margin (Jun 30 2022)
Q2 		(Mar 31 2022)
Q1 		(Dec 31 2021)
Q4 		(Sep 30 2021)
Q3 		(Jun 30 2021)
Q2
Y / Y Revenue Change -34.35 %
Seq. Revenue Change 1.13 %
Revenue In Millions $10.54
Gross Profit Margin 83.96 %
Gross Profit Margin Total Ranking # 434
Gross Profit In Millions $8.85
Y / Y Gross Profit Change -36.33 %
Seq. Gross Profit Change 7.17 %


Commenting Second Quarter 2022 Gross Profit Margin
La Jolla Pharmaceutical Company Gross Profit grew by 7.17 % in Q2 sequentially to 9 millions, while Revenue increased by 1.13 %, this led to improvement in the company's Gross Profit Margin to 83.96 %, Gross Profit Margin remained below La Jolla Pharmaceutical Company average.


Observing second quarter 2022 results within Biotechnology & Pharmaceuticals industry 11 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 434, from total ranking in the previous quarter at 597.
Learn about Gross Margin
LJPC's Gross Profit Margin second quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 12
Healthcare Sector # 87
Overall # 424

Gross Profit Margin Statistics
High Average Low
92.83 % 85.07 % 65.25 %
(Mar 31 2018)   (Dec 31 2020)


LJPC Gross Income Trends • More of LJPC's Profitabilty Ratios • LJPC Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
LJPC's Cumulative Gross Profit Margin
Biotechnology & Pharmaceuticals Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
LJPC's Gross Profit Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for LJPC's Competitors
Gross Profit Margin Profit Margin for La Jolla Pharmaceutical's Suppliers
Gross Profit Margin Profit Margin for LJPC's Customers

You may also want to know
LJPC's Annual Growth Rates LJPC's Profitability Ratios LJPC's Asset Turnover Ratio LJPC's Dividend Growth
LJPC's Roe LJPC's Valuation Ratios LJPC's Financial Strength Ratios LJPC's Gross Profit Growth
LJPC's Roa LJPC's Inventory Turnover Ratio LJPC's Growth Rates LJPC's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2022, within Biotechnology & Pharmaceuticals Industry Gross Profit MarginJun 30 2022 MRQ Gross ProfitJun 30 2022 MRQ Revenue
Biocryst Pharmaceuticals Inc   99.62 %$ 65.286  Millions$ 65.532  Millions
Neurocrine Biosciences Inc   98.73 %$ 373.400  Millions$ 378.200  Millions
Ginkgo Bioworks Holdings Inc   98.31 %$ 142.174  Millions$ 144.618  Millions
Exelixis Inc   96.79 %$ 405.946  Millions$ 419.427  Millions
Tarsus Pharmaceuticals Inc   96.58 %$ 14.755  Millions$ 15.277  Millions
Eiger Biopharmaceuticals Inc   96.31 %$ 3.940  Millions$ 4.091  Millions
Solid Biosciences Inc   95.66 %$ 5.901  Millions$ 6.169  Millions
Lineage Cell Therapeutics Inc   95.28 %$ 4.338  Millions$ 4.553  Millions
Agenus Inc  90.33 %$ 18.902  Millions$ 20.926  Millions
Aerie Pharmaceuticals Inc   88.77 %$ 29.570  Millions$ 33.311  Millions
Zeo Scientifix Inc   87.82 %$ 1.504  Millions$ 1.713  Millions
La Jolla Pharmaceutical Company  83.96 %$ 8.852  Millions$ 10.543  Millions
Biogen Inc   81.31 %$ 2,105.100  Millions$ 2,589.100  Millions
Coherus Oncology inc   81.25 %$ 48.874  Millions$ 60.151  Millions
Seagen Inc   78.67 %$ 391.402  Millions$ 497.502  Millions
Halozyme Therapeutics Inc   77.72 %$ 118.422  Millions$ 152.365  Millions
Amgen Inc   77.10 %$ 5,084.000  Millions$ 6,594.000  Millions
Gilead Sciences Inc   76.96 %$ 4,818.000  Millions$ 6,260.000  Millions
Orchard Therapeutics Plc  74.31 %$ 3.246  Millions$ 4.368  Millions
Oyster Point Pharma Inc   72.09 %$ 3.383  Millions$ 4.693  Millions
Acorda Therapeutics Inc   71.66 %$ 22.251  Millions$ 31.051  Millions
Clarus Therapeutics Holdings Inc.  71.36 %$ 2.890  Millions$ 4.050  Millions
Moderna Inc   70.92 %$ 3,368.000  Millions$ 4,749.000  Millions
Sorrento Therapeutics Inc   70.40 %$ 8.068  Millions$ 11.461  Millions
Adaptive Biotechnologies Corporation  69.72 %$ 30.439  Millions$ 43.660  Millions
Bio techne Corp  69.51 %$ 200.350  Millions$ 288.228  Millions
Vericel Corporation  61.69 %$ 22.854  Millions$ 37.046  Millions
Regenxbio Inc   60.33 %$ 19.698  Millions$ 32.649  Millions
Repligen Corp  58.46 %$ 121.373  Millions$ 207.633  Millions
Xtant Medical Holdings Inc   54.81 %$ 8.374  Millions$ 15.277  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.